Search tool

Changing dynamics in the heroin market, the latest implications of cannabis use and new features and dimensions of the stimulant and ‘new drugs’ scene are among the issues highlighted in the European...

Illicit opioid consumption during pregnancy brings with it the risk of an increase in obstetric complications for the mother and a range of potential dangers for the child, both before and after...

This report presents the data and findings of the risk assessment on the new psychoactive substance, MT-45, that was conducted by the Scientific Committee of the EMCDDA. Concerns over the availability and...

In April 2014, the EMCDDA and Europol examined the available information on a new psychoactive substance 1-cyclohexyl-4-(1,2-diphenylethyl)piperazine, commonly known as MT-45. The two organisations concluded that sufficient information had been accumulated to...

This report presents the data and findings of the risk assessment on the new psychoactive substance, 3,4-dichloro-N-{[1-(dimethylamino)cyclohexyl]methyl}benzamide (AH-7921), that was conducted by the Scientific Committee of the EMCDDA. Concerns over this synthetic...

The EMCDDA–Europol Joint Report on new psychoactive substance AH-7921 (3,4-dichloro-N-[[1-(dimethylamino)cyclohexyl]methyl]benzamide), submitted in December 2013 to the Council of the EU, the European Commission and the EMA. After assessing the available evidence, the...